Vitamin K antagonists and pregnancy outcome

Summary

Vitamin K antagonists (VKA) are known to act as teratogens; however, there is still uncertainty about the relative risk for birth defects and the most sensitive period. In a multi-centre (n=12), observational, prospective study we compared 666 pregnant women exposed to phenprocoumon (n=280), acenocoumarol (n=226), fluindione (n=99), warfarin (n=63) and phenindione (n=2) to a non-exposed control group (n=1,094). Data were collected by institutes collaborating in the European Network of Teratology Information Services (ENTIS) during individual risk counselling between 1988 and 2004. Main outcome measures were coumarin embryopathy and other birth defects, miscarriage rate, birth-weight, and prematurity. The rate of major birth defects after 1st trimester exposure was significantly increased (OR 3.86, 95% CI 1.86–8.00). However, there were only two coumarin embryopathies (0.6%; both phenprocoumon). Prematurity was more frequent (16.0% vs. 7.6%, OR 2.61, 95% CI 1.76–3.86), mean gestational age at delivery (37.9 vs. 39.4, p<0.001), and mean birth weight of term infants (3,166 g vs. 3,411 g; p<0.001) were lower compared to the controls. Using the methodology of survival analysis, miscarriage rate reached 42% vs. 14% (hazard ratio 3.36; 95% CI 2.28–4.93). In conclusion, use of VKA during pregnancy increases the risk of structural defects and other adverse pregnancy outcomes.The risk for coumarin embryopathy is, however, very small, in particular when therapy during the 1st trimester did not take place later than week 8 after the 1st day of the last menstrual period. Therefore, elective termination of a wanted pregnancy is not recommended if (inadvertent) exposure took place in early pregnancy. Close follow-up by the obstetrician including level II ultrasound should be recommended in any case of VKA exposure during pregnancy.

Key words

Pregnancy - coumarin derivatives - vitamin K antagonists - human - teratogenicity - spontaneous abortion

• References

• 1 Hall JG, Pauli RM, Wilson KM. Maternal and fetal sequelae of anticoagulation during pregnancy. Am J Med 1980; 68: 122-40.
• 2 Howe AM, Webster WS. The warfarin embryopathy: a rat model showing maxillonasal hypoplasia and other skeletal disturbances. Teratology 1992; 46: 379-90.
• 3 van Driel D, Wesseling J, Sauer PJ. et al. Teratogen update: Fetal effects after in utero exposure to coumarins: overview of cases, follow-up findings, and pathogenesis. Teratology 2002; 66: 127-40.
• 4 Ville Y, Jenkins E, Shearer MJ. et al. Fetal intraventricular haemorrhagia and maternal warfarin. Lancet 1993; 341: 1211.
• 5 Pauli RM, Haun J. Intrauterine effects of coumarin derivatives. Dev Brain Dysfunc 1993; 06: 229-47.
• 6 Clementi M, Di Gianantonio E, Ornoy A. Teratology information services in Europe and their contribution to the prevention of congenital anomalies. Community Genet 2002; 05: 8-12.
• 7 Eléfant E, Boyer M, Boyer P. et al. Teratogenic agent information centre: fifteen years of counseling and pregnancy follow-up. Teratology 1992; 46: 35-44.
• 8 Garbis JM, Robert E, Peters PWJ. Experience of two teratology information services in Europe. Teratology 1990; 42: 629-34.
• 9 Schaefer C, Hannemann D, Meister R. Post-marketing surveillance system for drugs in pregnancy - 15 years experience of ENTIS. Reprod Toxicol 2005; 20: 331-43.
• 10 Rasmussen SA, Olney RS, Holmes LB. et al. National Birth Defects Prevention Study. Guidelines for case classification for the National Birth Defects Prevention Study. Birth Defects Res (A) 2003; 67: 193-201.
• 11 Klein JP, Moeschberger ML. Survival analysis techniques for censored and truncated data. 2nd ed. New York: Springer; 2003
• 12 Kleinbaum D, Klein M. Survival Analysis. A selflearning text series: Statistics for biology and health. 2nd ed. New York: Springer; 1997
• 13 Vitale N, De Feo M, De Santo LS. et al. Dose-dependent fetal complications of warfarin in pregnant women with mechanical heart valves. J Am Coll Cardiol 1999; 33: 1637-41.
• 14 Cotrufo M, DeFeo M, DeSanto LS. et al. Risk of warfarin during pregnancy with mechanical valve prostheses. Obstet Gynecol 2002; 99: 35-40.
• 15 Balde MD, Breitbach GP, Wettstein A. et al. [Tetralogy of Fallot following coumarin administration in early pregnancy-an embryopathy?]. Geburtshilfe Frauenheilkd 1988; 48: 182-3.
• 16 Hall BD. Warfarin embryopathy and urinary tract anomalies: possible new association (letter). Am J Med Genet 1989; 34: 292-3.
• 17 Cox DR, Martin L, Hall BD. Asplenia syndrome after fetal exposure to warfarin. Lancet 1977; 26: 1134.
• 18 Ruthnum P, Tolmie JL. Atypical malformations in an infant exposed to warfarin during the first trimester of pregnancy. Teratology 1987; 36: 299-301.
• 19 Lapiedra OJ, Bernal JM, Ninot S. et al. Open heart surgery for thrombosis ofa prosthetic mitral valve during pregnancy. Fetal hydrocephalus. J Cardiovasc Surg (Torino) 1986; 27: 217-20.
• 20 van Driel D, Wesseling J, Sauer PJ. et al. In utero exposure to coumarins and cognition at8 to 14 years old. Pediatrics 2001; 107: 123-9.
• 21 van Driel D, Wesseling J, de Vries TW. et al. Coumarin embryopathy: long-term follow-up of two cases. Eur J Pediatr 2002; 161: 231-2.
• 22 Wesseling J, Van Driel D, Heymans HS. et al. Behavioural outcome of school-age children after prenatal exposure to coumarins. Early Hum Dev 2000; 58: 213-24.
• 23 Wesseling J, Van Driel D, Smrkovsky M. et al. Neurological outcome in school-age children after in utero exposure to coumarins. Early Hum Dev 2001; 63: 83-95.
• 24 Chong MK, Harvey D, de Swiet M. Follow-up study of children whose mothers were treated with warfarin during pregnancy. Br J Obstet Gynaecol 1984; 91: 1070-3.
• 25 Olthof E, De Vries TW, Touwen BC. et al. Late neurological, cognitive and behavioural sequelae of prenatal exposure to coumarins: a pilot study. Early Hum Dev 1994; 38: 97-109.
• 26 Wong V, Cheng CH, Chan KC. Fetal and neonatal outcome of exposure to anticoagulants during pregnancy. AmJ Med Genet 1993; 45: 17-21.
• 27 Felix RJ, Jones KL, Johnson KA. et al. for the Organization of Teratology Information Services (OTIS) Collaborative Research Group. Postmarketing surveillance for drug safety in pregnancy:The Organization of Teratology Information Services Project. Birth Defects Research (A) 2004; 70: 944-7.
• 28 Johnson KA, Weber PA, Jones KL. et al. Selection bias in teratology information service pregnancy outcome studies. Teratology 2001; 64: 79-82.
• 29 Martinez-Frias ML, Rodriguez-Pinilla E. The problems of using data from teratology information services (TIS) to identify putative teratogens. Teratology 1999; 60: 54-5.
• 30 Ornoy A, Mastroiacovo P. More on data from teratogen information systems (TIS). Teratology 2000; 61: 327-8.
• 31 Holmes LB. Need for inclusion and exclusion criteria for the structural abnormalities recorded in children born from exposed pregnancies. Teratology 1999; 64: 79-82.